A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France).
ELISA
SARS-CoV-2
antibodies
seroneutralization
seroprevalence
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
10 02 2022
10 02 2022
Historique:
received:
05
01
2022
revised:
03
02
2022
accepted:
07
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
3
3
2022
Statut:
epublish
Résumé
This study aimed to estimate the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the staff and student populations of the University of Corsica (France) during the second wave of the epidemic. A cross-sectional survey was conducted from 23 November 2020 to 31 January 2021. The participants underwent blood sampling using a fingerstick procedure and completed an anonymized questionnaire. Sera were tested for the presence of anti-SARS-CoV-2 IgG (ELISA-S) and, if positive, with an in-house virus neutralization test (VNT). A total of 418 persons were included in the study. The overall seroprevalence was 12.8% (95% confidence interval (CI), 9.8-16.6%). A total of 15 (31%) of the 49 individuals who had a positive ELISA-S also had a positive VNT. Seropositivity was associated with living at the city campus during the week and on weekends (OR = 3.74 [1.40-12.00]), using public transportation/carpooling (OR = 2.00 [1.01-4.02]), and being in contact with a person who tested positive for SARS-CoV-2 (OR = 2.32 [1.20-4.40]). The main symptoms associated with seropositivity were "having had an acute respiratory infection" (OR = 3.05 [1.43-6.43]) and "experiencing loss of smell" (OR = 16.4 [5.87-50.7]). These results could be useful for SARS-CoV-2 prevention and control on university campuses.
Identifiants
pubmed: 35206161
pii: ijerph19041953
doi: 10.3390/ijerph19041953
pmc: PMC8872171
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
EXCLI J. 2021 Feb 09;20:276-280
pubmed: 33628163
JAMA. 2020 Jun 2;323(21):2137-2138
pubmed: 32239184
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Emerg Microbes Infect. 2020 Dec;9(1):2509-2514
pubmed: 33238813
Int J Environ Res Public Health. 2021 Sep 22;18(19):
pubmed: 34639273
J Adolesc Health. 2020 Dec;67(6):763-768
pubmed: 33071164
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMC Public Health. 2021 Sep 19;21(1):1704
pubmed: 34538240
J Infect. 2021 Jul;83(1):104-111
pubmed: 33933527
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
Life (Basel). 2020 Sep 21;10(9):
pubmed: 32967110
Front Public Health. 2021 Jul 26;9:715192
pubmed: 34381756
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Clin Med. 2020 Nov 05;9(11):
pubmed: 33167563
J Med Internet Res. 2020 Oct 12;22(10):e19994
pubmed: 33001833
JMIR Public Health Surveill. 2021 Jan 11;7(1):e24320
pubmed: 33315576
Auris Nasus Larynx. 2020 Aug;47(4):565-573
pubmed: 32553562
Int J Environ Res Public Health. 2021 Feb 16;18(4):
pubmed: 33669412
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Int J Hyg Environ Health. 2020 Sep;230:113610
pubmed: 32896785
Lancet Reg Health Eur. 2021 Aug;7:100148
pubmed: 34124709
Trop Med Int Health. 2009 Nov;14 Suppl 1:14-20
pubmed: 19508436
Nat Commun. 2020 May 29;11(1):2800
pubmed: 32472043